<DOC>
	<DOC>NCT00141492</DOC>
	<brief_summary>This study is to investigate how well Androgel, when tested against placebo gel, helps to control blood sugar levels in males with type 2 diabetes who have low testosterone (the main male hormone) blood levels and are taking oral diabetic medicines alone or in combination with insulin.</brief_summary>
	<brief_title>Efficacy and Safety of Androgel in the Treatment of Hypogonadal and Low Testosterone Men With Type 2 Diabetes</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus, Type 2</mesh_term>
	<mesh_term>Hypogonadism</mesh_term>
	<mesh_term>Testosterone</mesh_term>
	<mesh_term>Testosterone enanthate</mesh_term>
	<mesh_term>Testosterone undecanoate</mesh_term>
	<mesh_term>Testosterone 17 beta-cypionate</mesh_term>
	<mesh_term>Methyltestosterone</mesh_term>
	<criteria>1. Able to read and write 2. Males 3. Between 3080 years old 4. Have type 2 diabetes 5. Diagnoses of hypogonadism or low testosterone 1. On insulin monotherapy 2. Use of testosterone therapy within the last 6 months 3. Male breast cancer 4. History of prostate cancer 5. History of clinically significant sleep apnea</criteria>
	<gender>Male</gender>
	<minimum_age>30 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>January 2009</verification_date>
	<keyword>Type 2 diabetes</keyword>
	<keyword>hypogonadism</keyword>
	<keyword>testosterone</keyword>
	<keyword>glycosylated hemoglobin A1C</keyword>
</DOC>